DNA methylation inhibitors: Research advances

Journal of International Pharmaceutical Research

Volumn 37, Issue 3, 2010, Pages 198-202

  Li, Pei Kun ^a   Geng, Xiao Ping ^a   Zhu, Li Xin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Antineoplastic agents; DNA methylation,inhibitors; DNA methyltransferase; Nucleosides

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; FAZARABINE; ZEBULARINE;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; DEMETHYLATION; DNA METHYLATION; DNA MODIFICATION; ENZYME ACTIVITY; ENZYME MECHANISM; EPIGENETICS; HUMAN; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 77954482459     PISSN: 16740440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Jones PA, Tukai D. The role of DNA methylation in mammalian epigenetics [J]. Science, 2001,293(5532):1068-1070.
2. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene [J]. Cancer Cell, 2003,3(1):89-95. (Pubitemid 37443893)
3. Kurkjian C, Kummar S, Murgo AJ, et al. DNA methylation: its role in cancer development and therapy [J]. Curr Probl Cancer, 2008,32(5):187-235.
4. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes [J]. Semin Hematol, 2008,45(1):23-30.
5. Kaminskas E, Farrell AT, Wang YC, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension [J]. Oncologist, 2005,10(3):176-182. (Pubitemid 40463154)
6. Momparler RL. Pharmacology of 5-aza-2′-deoxycytidine (decitabine) [J]. Semin Hematol, 2005,42(1):S9-S16.
7. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine [J]. Nat Rev Drug Discov, 2005,4(4):275-276.
8. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes [J]. Clin Cancer Res, 2005,11(10):3604-3608.
9. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate [J]. J Clin Oncol, 2005,23(17):3948-3956. (Pubitemid 46218698)
10. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study [J]. Cancer, 2006,106(8):1794-1803.
11. Samlowski WE, Leachman SA, Wade M, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation [J]. J Clin Oncol, 2005,23(17):3897-3905.
12. Gollob JA, Sclambi CJ, Peterson BL, et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma [J]. Clin Cancer Res, 2006,12(15):4619-4627.
13. Scott SA, Lakshimikuttysamma A, Sheridan DP, et al. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression [J]. Exp Hematol, 2007,35(2):263-273.
14. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies [J]. J Natl Cancer Inst, 2005,97(20):1498-1506. (Pubitemid 41631949)
15. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors - state of the art [J]. Ann Oncol, 2002,13(11):1699-1716.
16. Lee BH, Yegnasubramanian S, Lin X, et al. Procainamide is a specific inhibitor of DNA methyltransferase 1 [J]. J Biol Chem, 2005,280(49):40749-40756.
17. Zaveri NT. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications [J]. Life Sci, 2006,78(18):2073-2080.
18. Gao Z, Xu Z, Hung MS, et al. Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells [J]. Anticancer Res, 2009,29(6):2025-2030.
19. Gu B, Ding Q, Xia G, et al. EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression [J]. Oncol Rep, 2009,21(3):635-640.
20. Kato K, Long NK, Makita H, et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells [J]. Br J Cancer, 2008,99(4):647-654.
21. Rubin RL. Drug-induced lupus [J]. Toxicology, 2005,209(2):135-147.
22. Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus [J]. Autoimmunity, 2005,38(7):507-518.
23. Song Y, Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and reexpression [J]. Cancer Chemother Pharmacol, 2009,63(4):605-613.
24. Candelaria M, Gallardo-Rincón D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors [J]. Ann Oncol, 2007,18(9):1529-1538.
25. Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, et al. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine [J]. J Transl Med, 2006,4(32):1-13.
26. Arce C, Segura-Pacheco B, Perez-Cardenas E, et al. Hydralazine target: from blood vessels to the epigenome [J]. J Transl Med, 2006,4(10):1-16.
27. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases [J]. Cancer Res, 2005,65(14):6305-6311.
28. Siedlecki P, Garcia Boy R, Musch T, et al. Discovery of two novel small-molecule inhibitors of DNA methylation [J]. J Med Chem, 2006,49(2):678-683.
29. Stresemann C, Brueckner B, Musch T, et al. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines [J]. Cancer Res, 2006,66(5):2794-2800.
30. Klisovic RB, Stock W, Cataland S, et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia [J]. Clin Cancer Res, 2008,14(8):2444-2449.
31. Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors [J]. Clin Cancer Res, 2009,15(9):3177-3183.
32. Cui X, Wakai T, Shirai Y, et al. Arsenic trioxide nhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells [J]. Hum Pathol, 2006,37(3):298-311. (Pubitemid 43277518)
33. 3 on demethylation of SHP-1 gene in human lymphoma cell line T2 [J]. Chin J Cancer, 2009,28(3):209-213.